Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)
 
 • Company Description   
Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif.

Number of Employees: 323

 
 • Price / Volume Information   
Yesterday's Closing Price: $44.20 Daily Weekly Monthly
20 Day Moving Average: 645,316 shares
Shares Outstanding: 42.01 (millions)
Market Capitalization: $1,857.03 (millions)
Beta: 0.94
52 Week High: $57.28
52 Week Low: $20.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.28% -16.08%
12 Week -11.99% -7.91%
Year To Date -20.17% -19.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
15440 LAGUNA CANYON ROAD SUITE 160
-
IRVINE,CA 92618
USA
ph: 949-418-1801
fax: -
dnakasone@tarsusrx.com http://www.tarsusrx.com
 
 • General Corporate Information   
Officers
Bobak Azamian - President; Chief Executive Officer and Chairman
Jeffrey Farrow - Chief Financial Officer and Chief Strategy Officer
Scott Morrison - Director
Bhaskar Chaudhuri - Director
Andrew Goldberg - Director

Peer Information
Tarsus Pharmaceuticals, Inc. (CORR.)
Tarsus Pharmaceuticals, Inc. (RSPI)
Tarsus Pharmaceuticals, Inc. (CGXP)
Tarsus Pharmaceuticals, Inc. (BGEN)
Tarsus Pharmaceuticals, Inc. (GTBP)
Tarsus Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87650L103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 42.01
Most Recent Split Date: (:1)
Beta: 0.94
Market Capitalization: $1,857.03 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.26 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 50.76% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.42
Price/Cash Flow: -
Price / Sales: 7.95
EPS Growth
vs. Year Ago Period: 36.63%
vs. Previous Quarter: -6.67%
Sales Growth
vs. Year Ago Period: 183.68%
vs. Previous Quarter: 17.96%
ROE
03/31/25 - -39.72
12/31/24 - -46.71
09/30/24 - -55.86
ROA
03/31/25 - -25.74
12/31/24 - -31.24
09/30/24 - -39.28
Current Ratio
03/31/25 - 5.57
12/31/24 - 4.43
09/30/24 - 5.42
Quick Ratio
03/31/25 - 5.54
12/31/24 - 4.39
09/30/24 - 5.38
Operating Margin
03/31/25 - -44.91
12/31/24 - -63.16
09/30/24 - -103.64
Net Margin
03/31/25 - -44.91
12/31/24 - -63.16
09/30/24 - -103.64
Pre-Tax Margin
03/31/25 - -44.91
12/31/24 - -63.16
09/30/24 - -103.64
Book Value
03/31/25 - 8.15
12/31/24 - 5.87
09/30/24 - 6.24
Inventory Turnover
03/31/25 - 6.32
12/31/24 - 4.39
09/30/24 - 2.99
Debt-to-Equity
03/31/25 - 0.21
12/31/24 - 0.32
09/30/24 - 0.30
Debt-to-Capital
03/31/25 - 17.37
12/31/24 - 24.24
09/30/24 - 23.19
 

Powered by Zacks Investment Research ©